Talphera, Inc. (NASDAQ:TLPH – Free Report) – Stock analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Talphera in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will earn ($0.17) per share for the quarter, up from their previous forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Talphera’s Q2 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.86) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.46) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at $0.09 EPS and FY2028 earnings at $0.09 EPS.
TLPH has been the subject of several other research reports. RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Talphera in a research note on Tuesday, January 28th. They issued a “buy” rating and a $4.00 price objective for the company.
Talphera Stock Performance
Talphera stock opened at $0.57 on Friday. The company’s 50 day simple moving average is $0.60 and its 200-day simple moving average is $0.71. Talphera has a 1 year low of $0.45 and a 1 year high of $1.27. The company has a market capitalization of $9.70 million, a price-to-earnings ratio of -0.83 and a beta of 0.20.
Talphera (NASDAQ:TLPH – Get Free Report) last posted its earnings results on Monday, March 31st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.14.
Talphera Company Profile
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Featured Stories
- Five stocks we like better than Talphera
- What is the FTSE 100 index?
- Sportsman’s Warehouse Trading Volume Spike Signals Opportunity
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- AI Arms Race: U.S. vs China—These 4 Stocks Stand Out
- Growth Stocks: What They Are, Examples and How to Invest
- Charles Schwab Stock: Trading Up in a Down Market
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
